Michiko Hamada

ORCID: 0000-0002-5942-9800 · 2 papers in corpus

article 2023

The addition of dydrogesterone improves the outcomes of pregnant women with low progesterone levels when receiving vaginal progesterone alone as luteal support in HRT‐FET cycles

Reproductive medicine and biology ·doi:10.1002/rmb2.12511

Purpose: Vaginal progesterone (VP) alone has been used as luteal support (LS) in HRT-FET cycles without measuring serum progesterone concentrations (SPC) because it can achieve adequate intrauterine progesterone levels. However, several rep…

2022

A novel orally active gonadotropin-releasing hormone antagonist, relugolix, is a potential substitute for injectable GnRH antagonists in controlled ovarian stimulation in assisted reproductive technology.

Reproductive medicine and biology ·doi:10.1002/rmb2.12424

PurposeTo evaluate the efficacy of an oral gonadotropin-releasing hormone antagonist (GnRH Ant), relugolix (R), for assisted reproductive technology (ART).MethodsWe enrolled women undergoing ART using a GnRH Ant for controlled ovarian stimu…